Core Viewpoint - The company is currently in the process of calculating its financial data for 2025, indicating ongoing assessments and potential future developments in its financial performance [1] Group 1: Revenue Breakdown - For the fiscal year 2024, the company's foreign revenue is expected to account for approximately 8% of total revenue [1] - Within the foreign revenue, the European Union region is projected to represent about 20%-25% [1] Group 2: Sales Channels - The company utilizes both European cooperative agents for sales and direct collaborations with local chain testing laboratories and hospitals in the EU for distribution [1]

Core Viewpoint - The announcement reveals that three key shareholders of Kangwei Century (688426.SH) plan to reduce their holdings, which will not significantly impact the company's governance or ongoing operations [1][2]. Shareholder Reduction Plans - Shareholder Zhuang Zhihua intends to reduce up to 21,958 shares, representing 0.0195% of the total share capital - Shareholder Qi Yubai plans to reduce up to 11,311 shares, accounting for 0.0101% of the total share capital - Shareholder Yin Jianfeng aims to reduce up to 9,981 shares, which is 0.0089% of the total share capital - The total reduction by these three shareholders will not exceed 43,250 shares, or 0.0385% of the total share capital, with the reduction period set from February 5, 2026, to May 5, 2026 [1][2]. Shareholding Structure - As of the announcement date, Zhuang Zhihua holds 208,930 shares (0.1857% of total share capital), with 121,098 shares held indirectly through a management consulting partnership and 87,832 shares from a 2021 stock incentive plan - Qi Yubai holds 163,872 shares (0.1457% of total share capital), with 118,625 shares held indirectly and 45,247 shares from the 2021 stock incentive plan - Yin Jianfeng holds 116,818 shares (0.1038% of total share capital), with 76,894 shares held indirectly and 39,924 shares from the 2021 stock incentive plan [2]. Company Listing and Financials - Kangwei Century was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 25, 2022, with an issue price of 48.98 yuan per share and a total of 23,290,278 shares issued, of which 25% were publicly offered - The total funds raised amounted to 1,140.7578 million yuan, with a net amount of 1,054.3036 million yuan after deducting issuance costs, exceeding the original fundraising plan by 68.6277 million yuan - The funds are intended for projects related to medical devices, marketing network construction, molecular detection product R&D, and working capital [3][4].

Core Viewpoint - Jiangsu Kangwei Century Biotechnology Co., Ltd. announced a share reduction plan involving some directors and senior management due to personal financial needs related to tax obligations from the stock option incentive plan [3][10]. Summary by Sections Shareholding Information - As of the announcement date, key personnel hold the following shares: - Ms. Zhuang Zhihua: 208,930 shares (0.1857% of total shares), with 121,098 shares held indirectly through an employee stock ownership platform [2]. - Mr. Qi Yubai: 163,872 shares (0.1457% of total shares), with 118,625 shares held indirectly [2]. - Mr. Yin Jianfeng: 116,818 shares (0.1038% of total shares), with 76,894 shares held indirectly [2]. Reduction Plan Details - The reduction plan includes: - Ms. Zhuang Zhihua: up to 21,958 shares (0.0195% of total shares) - Mr. Qi Yubai: up to 11,311 shares (0.0101% of total shares) - Mr. Yin Jianfeng: up to 9,981 shares (0.0089% of total shares) - The reduction period is set for three months starting 15 trading days after the announcement [3][6]. Background on Shareholding - The mentioned directors and senior management have not reduced their holdings since the company went public on October 25, 2022 [5]. Compliance and Commitments - The reduction plan aligns with previous commitments made under the 2021 stock option incentive plan, which restricts the transfer of shares for 36 months post-exercise [8][9]. - The company confirms that the reduction does not violate any regulations regarding shareholding reductions [11].

Group 1 - The company 康为世纪 announced a share reduction plan involving three individuals due to personal financial needs and tax obligations related to the 2021 stock option incentive plan [1] -庄志华 plans to reduce up to approximately 22,000 shares, accounting for 0.0195% of the total share capital [1] - 戚玉柏 intends to reduce up to approximately 11,300 shares, representing 0.0101% of the total share capital [1] - 殷剑峰 aims to reduce up to 9,981 shares, which is 0.0089% of the total share capital [1] - The reduction period will commence 15 trading days after the announcement and will last for three months [1] Group 2 - The article mentions 海利生物, which has seen a ninefold increase in valuation through acquisitions, yet its valuation has halved in eight months [1] - The first major client of 海利生物 is a company that has not yet been established, indicating unusual circumstances surrounding its business operations [1]

证券代码：688426 证券简称：康为世纪 公告编号：2026-005 江苏康为世纪生物科技股份有限公司 部分董事、高级管理人员减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 税及其他个人资金需求，庄志华女士拟减持数量不超过 21,958 股，即不超过公 司总股本的 0.0195%；戚玉柏先生拟减持数量不超过 11,311 股，即不超过公司总 股本的 0.0101%；殷剑峰先生拟减持数量不超过 9,981 股，即不超过公司总股本 的 0.0089%。减持期间均为本公告披露之日起 15 个交易日之后的 3 个月内。 如遇派息、送股、转增股本、配股等除权除息事项，上述拟减持股份数量将 相应进行调整，但减持股份占公司总股本的比例不变。 | 股东名称 | 戚玉柏 | | | | --- | --- | --- | --- | | 股东身份 | 控股股东、实控人及一致行动人 | □是 | √否 | | | 直接持股 5%以上股东 | □是 | √否 | | | 董事、监事和高级管理人员 | √是 | □ ...

江苏康为世纪生物科技股份有限公司 2026 年第一次临时股东会会议资料 江苏康为世纪生物科技股份有限公司 2026 年第一次临时股东会会议须知 2026 年第一次临时股东会 会议资料 二○二六年一月 江苏康为世纪生物科技股份有限公司 2026 年第一次临时股东会会议资料 目录 | 2026 | 年第一次临时股东会会议须知 | 3 | | --- | --- | --- | | 2026 | 年第一次临时股东会会议议程 | 5 | | 2026 | 年第一次临时股东会会议议案 | 6 | | | 议案一《关于终止实施 年限制性股票激励计划的议案》 2024 | 6 | 2 / 7 江苏康为世纪生物科技股份有限公司 2026 年第一次临时股东会会议资料 江苏康为世纪生物科技股份有限公司 为了维护全体股东的合法权益，确保公司股东会的正常秩序和议事效率，根 据《中华人民共和国公司法》、《中华人民共和国证券法》、《上市公司股东会规则》、 《江苏康为世纪生物科技股份有限公司章程》和《江苏康为世纪生物科技股份有 限公司股东会议事规则》等相关规定，制订以下会议须知，请出席股东会的全体 人员遵照执行。 一、会议期间，全体出席人 ...

Group 1 - The company has decided to terminate the 2024 Restricted Stock Incentive Plan due to significant changes in the macroeconomic environment and market conditions since its introduction, which rendered the performance assessment indicators ineffective [7][61] - The board of directors approved the termination on January 9, 2026, and the decision will be submitted for shareholder approval [5][10] - The plan's termination includes the cancellation of 1,590,600 shares that were granted but not vested, along with the associated documents [5][7][61] Group 2 - The company will continue to optimize its compensation system and internal performance evaluation mechanisms to ensure effective employee motivation and support long-term development [8][61] - The termination of the incentive plan is in compliance with relevant laws and regulations, ensuring no harm to the interests of the company and its shareholders [9][13] - The company will handle the related share payment expenses according to accounting standards, with the final impact on net profit to be determined by an audit report [9][10] Group 3 - The company has also approved the continued use of temporarily idle raised funds for cash management, with a maximum amount of up to RMB 150 million [16][18] - The funds will be used for purchasing safe, liquid, and principal-protected financial products, ensuring that the investment does not affect the normal operation of the fundraising projects [20][21] - The decision to manage idle funds was made to enhance the efficiency of fund usage and increase returns for shareholders [28][30]

Group 1 - The company will hold its first extraordinary general meeting of 2026 on January 28, 2026, at 14:40 [2][61] - The meeting will take place at the company's headquarters in Jiangsu Province [2][61] - Shareholders can vote through the Shanghai Stock Exchange's online voting system on the day of the meeting [3][5] Group 2 - The company plans to continue using up to RMB 150 million of temporarily idle raised funds for cash management, focusing on safe and liquid financial products [23][29] - The decision to use idle funds was approved by the board on January 9, 2026, and is valid for 12 months [24][35] - The company aims to enhance the efficiency of fund usage and increase returns for shareholders [28][34] Group 3 - The company has decided to terminate the 2024 restricted stock incentive plan due to changes in the macroeconomic environment and market conditions [41][59] - The termination of the plan includes the cancellation of 1,590,600 shares that were granted but not vested [45][59] - The board believes that this decision will not adversely affect the company's daily operations or shareholder interests [48][51]

Group 1 - The company announced the approval of a proposal to continue using temporarily idle raised funds for cash management, with a maximum amount not exceeding RMB 150 million [1] - The funds will be used to purchase high-security, high-liquidity, and principal-protected financial products or deposit-type products, including but not limited to structured deposits, time deposits, and large-denomination certificates of deposit [1] - The usage period for these funds is effective for 12 months from the date of board approval, starting after the expiration of the previous authorization period on January 11, 2026, allowing for rolling use of the funds within the specified limit and timeframe [1]

Group 1 - The company, Kangwei Century, announced that it will hold its first extraordinary general meeting of shareholders for 2026 on January 28, 2026 [1]